Abstract: The invention features compositions and methods for treating anaplastic lymphoma kinase (ALK)-rearranged neoplasias including Non-Small Cell Lung Cancers (NSCLCs). The methods involve administering to a subject ALK peptides and/or polynucleotides encoding the ALK peptides, optionally in combination with an immune checkpoint inhibitor (ICI) and/or an ALK tyrosine kinase inhibitor (TKI).
Type:
Application
Filed:
November 4, 2024
Publication date:
February 20, 2025
Applicant:
The Children's Medical Center Corporation
Abstract: Provided herein are antisense oligonucleotides for use in targeting SARS-CoV-2. Also provided herein are compositions comprising such oligonucleotides and methods for administering the oligonucleotides or compositions thereof to a subject for the purpose of treating or preventing a SARS-CoV-2 infection.
Type:
Application
Filed:
December 16, 2022
Publication date:
February 20, 2025
Applicant:
The Children's Medical Center Corporation
Abstract: The invention features a prospective respiratory motion compensation technique for cardiovascular magnetic resonance imaging of the whole-heart of a free-breathing subject.
Type:
Grant
Filed:
September 26, 2023
Date of Patent:
February 18, 2025
Assignee:
The Children's Medical Center Corporation
Inventors:
Mehdi H. Moghari, Andrew J. Powell, Tal Geva
Abstract: Provided herein are compositions comprising compounds of Formula (I), and salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, and isotopically enriched derivatives thereof; for example, in the form of a particle (e.g., liposome). Also provided are methods, uses, pharmaceutical compositions, and kits involving the compounds and/or compositions described herein, for methods for delivering an agent described herein (e.g., therapeutic agent, diagnostic agent), or for treating and/or preventing a disease in a subject, and methods of synthesizing these compositions.
Type:
Application
Filed:
December 6, 2022
Publication date:
February 13, 2025
Applicant:
The Children's Medical Center Corporation
Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
Type:
Application
Filed:
October 31, 2024
Publication date:
February 13, 2025
Applicants:
Children's Medical Center Corporation, Politecnico di Milano, Dana-Farber Cancer Institute, Inc.
Abstract: Described herein are a ApoA1 and ApoM (A1M) fusion proteins, lipidated A1M fusion proteins, nanoparticles comprising AM1 fusion proteins, and methods of use thereof for treatment of vascular and inflammatory disorders.
Type:
Application
Filed:
September 30, 2022
Publication date:
February 6, 2025
Applicant:
The Children's Medical Center Corporation
Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described for proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease, in a subject in need thereof. Using the compound as a vaccine adjuvant enables effective immunization in vulnerable populations.
Type:
Application
Filed:
September 29, 2022
Publication date:
February 6, 2025
Applicant:
The Children's Medical Center Corporation
Inventors:
David J. Dowling, Ofer Levy, Simon D. van Haren, Katherine Chew, Dheeraj Soni, Maria De Leon
Abstract: Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBF? inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
February 4, 2025
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: Scan time in diffusion-relaxation magnetic resonance imaging (“MRI”) is reduced by implementing time-division multiplexing (“TDM”). In general, time-shifted radio frequency (“RF”) pulses are used to excite two or more imaging volumes. These RF pulses are applied to induce separate echoes for each slice. Diffusion MRI data can thus be acquired with different echo times, or alternatively with the same echo time, in significantly reduced overall scan time. Multidimensional correlations between diffusion and relaxation parameters can be estimated from the resulting data.
Type:
Grant
Filed:
June 3, 2021
Date of Patent:
February 4, 2025
Assignees:
The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
Inventors:
Lipeng Ning, Yogesh Rathi, Yang Ji, Borjan Gagoski
Abstract: Provided herein are nucleic acid-based nanoswitches that can detect specific nucleic acids and other analytes types by for example a simple gel electrophoresis readout. Binding of the target to the nanoswitches induces a conformation change from a linear, open conformation to a looped, closed conformation. These nanoswitches may be used in diagnostic assays such as nucleic acid-based diagnostic assays, to detect, measure and/or purify a variety of targets including low abundance targets.
Type:
Application
Filed:
August 7, 2024
Publication date:
January 30, 2025
Applicants:
The Research Foundation for The State University of New York, Children's Medical Center Corporation
Inventors:
Arun Richard Chandrasekaran, Clinton H. Hansen, Mounir Ahmad Koussa, Kenneth Anders Halvorsen, Wesley Philip Wong
Abstract: The technologies as described herein relate to compositions and methods for the treatment of hemoglobinopathies by increasing fetal hemoglobin in a subject.
Type:
Application
Filed:
October 14, 2022
Publication date:
January 30, 2025
Applicants:
THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE
Inventors:
David A. WILLIAMS, Daniel E. BAUER, Christian BRENDEL
Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
Type:
Application
Filed:
September 24, 2024
Publication date:
January 16, 2025
Applicants:
The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
Abstract: An ongoing pain detection system and method are provided. The method includes obtaining imaging data from patient using functional near-infrared spectroscopy from at least one cortical region of the brain of a non-responsive patient and observing power spectral density variations in the signal. The measured imaging data is compared with patient pain based on control data to recognize ongoing pain in the non-responsive patient.
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
January 7, 2025
Assignees:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Robert S. Langer, Daniel G. Anderson
Abstract: Methods, systems, and cooptation measurement devices as described herein include an elongate sensor body at the end of a proximal connecting member, and a plurality of sensors in an array across a face of the sensor body, wherein each sensor of the plurality of sensors is configured to detect if a portion of a heart valve is in contact with the sensor.
Abstract: Provided herein, inter alia, are improved methods for detecting analytes, including proteins and nucleic acids. In some instances, the analytes are detected in complex matrices such as serum.
Type:
Application
Filed:
June 21, 2024
Publication date:
January 2, 2025
Applicant:
Children's Medical Center Corporation
Inventors:
Clinton H. Hansen, Wesley Philip Wong, Darren Yang, Andrew Ward
Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described.
Type:
Application
Filed:
September 29, 2022
Publication date:
January 2, 2025
Applicant:
The Children's Medical Center Corporation
Inventors:
Ofer Levy, David J. Dowling, Simon D. van Haren, Katherine Chew, Yoshine Saito
Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
December 31, 2024
Assignees:
Wake Forest University Health Sciences Genethon, Children's Medical Center Corporation
Inventors:
Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello